Category: Prof. Erika Lietzan ⋅ Page 4

Professor Lietzan Participates in Center for the Protection of Intellectual Property Summer Institute

Professor Erika Lietzan recently attended the 2017 Summer Institute, hosted by the Center for the Protection of Intellectual Property at Antonin Scalia Law School, George Mason University. She presented “The Drug Innovation Paradox,” which will be published by the Missouri Law Review next year, explains that the United States has chosen to incentivize drug innovation with a period of exclusive…

Objective Intent: Professor Lietzan’s New Blog Focuses on Food and Drug Administration

Professor Erika Lietzan has launched a new blog, Objective Intent. In this blog, she and a co-author, Professor Patricia Zettler of Georgia State University, explore legal and policy issues associated with the U.S. Food and Drug Administration (FDA). Before joining the faculty of the University of Missouri, Professor Lietzan practiced FDA law for 18 years with one of the country’s…

Professor Lietzan Named Affiliate Scholar of Center for the Protection of Intellectual Property

Professor Erika Lietzan has been named an Affiliate Scholar at the Center for the Protection of Intellectual Property, part of George Mason University’s Antonin Scalia Law School. She is also currently the recipient of an Thomas Edison Innovation Fellowship and a Leonardo da Vinci Fellowship Grant, both from the center, for a large historical and empirical project relating to restoration…

Professor Lietzan to Attend Economics Institute for Law Professors

Professor Erika Lietzan was selected to attend the Thirty-Third Economics Institute for Law Professors, hosted by the Henry G. Manne Program in Law and Economic Studies at the Antonin Scalia Law School at George Mason University. Professor Lietzan researches, writes and teaches primarily in the areas of drug and device regulation, intellectual property and administrative law. This eight-day program is designed…

Professor Lietzan Files Amicus Brief with U.S. Supreme Court in Patent Case

Professor Lietzan recently filed an amicus brief in the United States Supreme Court, in a closely-watched case involving patent litigation under the Biologics Price Competition and Innovation Act (BPCIA). The appellate court concluded that biosimilar applicants may elect not to comply with the information exchange provisions laid out in the statute, effectively opting out of the statutory premarket patent litigation…

Professor Lietzan Quoted on Selection of FDA Commissioner

Professor Erika Lietzan was recently quoted in BuzzFeed News regarding President Donald Trump’s selection of Dr. Scott Gottlieb to be the next commissioner of the U.S. Food & Drug Administration. Dr. Gottlieb was deputy commissioner under President George W. Bush and is currently a resident fellow at the American Enterprise Institute. Professor Lietzan noted that Dr. Gottlieb has a broad…

Citizen Petitions at the FDA: Professor Lietzan Interviewed by The Atlantic

Professor Erika Lietzan was recently interviewed by a reporter for The Atlantic in connection with the use of “citizen petitions” at the U.S. Food & Drug Administration (FDA). A recent article in the New England Journal of Medicine had pointed out that many petitions are filed by brand-name drug companies about products proposed by generic drug companies. Professor Lietzan commented…

Professor Lietzan Quoted on “Right to Try” Legislation

Professor Erika Lietzan was recently quoted in numerous papers around the country in connection with possible federal “right to try” legislation. Broadly speaking, the purpose of state “right to try” laws is to make it possible for terminally ill patients to receive unapproved drugs for treatment, if those drugs are currently in clinical trials and certain other conditions are met.…